Literature DB >> 17320281

Inhibin as a diagnostic marker for ovarian cancer.

David M Robertson1, Enid Pruysers, Tom Jobling.   

Abstract

The inhibins are a family of growth factors comprised of several different species that are secreted in the female principally from the ovarian follicle. The inhibins perform best as markers of ovarian cancer when measured collectively (total inhibin) by immunoassays targeted to common epitopes. After menopause with the depletion of ovarian follicles, the circulating level of total inhibin becomes undetectable. In contrast, serum total inhibin levels are elevated in women with ovarian cancer, in particular those with granulosa cell tumours and those with the mucinous subtype of epithelial carcinoma. Investigations into the clinical utility of inhibin to detect ovarian cancer have shown that it complements CA125, an established marker of epithelial ovarian cancer, in that each performs best in detecting different subtypes of ovarian cancer. In some published studies, the two markers together have detected up to 95% of ovarian cancers with 95% specificity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17320281     DOI: 10.1016/j.canlet.2006.12.017

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  12 in total

1.  Genome-wide screening of indicator genes for assessing the potential carcinogenic risk of Nanjing city drinking water.

Authors:  Rui Zhang; Shupei Cheng; Aimin Li; Jie Sun; Yan Zhang; Xuxiang Zhang
Journal:  Ecotoxicology       Date:  2011-03-22       Impact factor: 2.823

Review 2.  Inhibin at 90: from discovery to clinical application, a historical review.

Authors:  Yogeshwar Makanji; Jie Zhu; Rama Mishra; Chris Holmquist; Winifred P S Wong; Neena B Schwartz; Kelly E Mayo; Teresa K Woodruff
Journal:  Endocr Rev       Date:  2014-07-22       Impact factor: 19.871

3.  Inhibin Is a Novel Paracrine Factor for Tumor Angiogenesis and Metastasis.

Authors:  Priyanka Singh; Laura M Jenkins; Ben Horst; Victoria Alers; Shrikant Pradhan; Prabhjot Kaur; Tapasya Srivastava; Nadine Hempel; Balázs Győrffy; Eugenia V Broude; Nam Y Lee; Karthikeyan Mythreye
Journal:  Cancer Res       Date:  2018-03-13       Impact factor: 12.701

4.  Computed tomography and magnetic resonance imaging features of ovarian fibrothecoma.

Authors:  Jingya Chen; Jianhua Wang; Xiao Chen; Yaohui Wang; Zhongqiu Wang; Dake Li
Journal:  Oncol Lett       Date:  2017-05-22       Impact factor: 2.967

5.  Association of Anti-Mullerian Hormone, Follicle-Stimulating Hormone, and Inhibin B with Risk of Ovarian Cancer in the Janus Serum Bank.

Authors:  Sarah R Irvin; Elisabete Weiderpass; Frank Z Stanczyk; Louise A Brinton; Britton Trabert; Hilde Langseth; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-01-13       Impact factor: 4.254

6.  ID2 and GJB2 promote early-stage breast cancer progression by regulating cancer stemness.

Authors:  Yin Liu; Puspa R Pandey; Sambad Sharma; Fei Xing; Kerui Wu; Amar Chittiboyina; Shih-Ying Wu; Abhishek Tyagi; Kounosuke Watabe
Journal:  Breast Cancer Res Treat       Date:  2019-02-06       Impact factor: 4.872

7.  Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet?

Authors:  Dimitra Sasaroli; George Coukos; Nathalie Scholler
Journal:  Biomark Med       Date:  2009-06-01       Impact factor: 2.851

8.  Inhibin/activin-betaE subunit in normal and malignant human cervical tissue and cervical cancer cell lines.

Authors:  Florian Bergauer; Ansgar Brüning; Naim Shabani; Thomas Blankenstein; Julia Jückstock; Darius Dian; Ioannis Mylonas
Journal:  J Mol Histol       Date:  2009-12-24       Impact factor: 2.611

9.  Enhanced efficacy and specificity of epithelial ovarian carcinogenesis by embedding a DMBA-coated cloth strip in the ovary of rat.

Authors:  Yiping Huang; Wei Jiang; Yisheng Wang; Yufang Zheng; Qing Cong; Congjian Xu
Journal:  J Ovarian Res       Date:  2012-09-03       Impact factor: 4.234

10.  Spontaneous transformation of human granulosa cell tumours into an aggressive phenotype: a metastasis model cell line.

Authors:  Misa Imai; Miho Muraki; Kiyoshi Takamatsu; Hidekazu Saito; Motoharu Seiki; Yuji Takahashi
Journal:  BMC Cancer       Date:  2008-11-04       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.